Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
Neurocrine Biosciences (Nasdaq: NBIX) announced positive results from its Phase 2 SAVITRI™ study of osavampator (NBI-1065845) for major depressive disorder (MDD). The study demonstrated statistically significant improvements in depression severity at both Day 28 and Day 56 with 1 mg daily oral dosing.
The trial, involving 183 adults, tested two doses (1 mg and 3 mg) against placebo. The 1 mg dose achieved the primary endpoint with significant MADRS score reduction and showed superior results in treatment response and remission rates. Osavampator, a first-in-class selective AMPA-PAM, was well-tolerated with no serious adverse events, with headache and nasopharyngitis being the most common side effects.
Neurocrine Biosciences (Nasdaq: NBIX) ha annunciato risultati positivi dal suo studio di fase 2 SAVITRI™ su osavampator (NBI-1065845) per il disturbo depressivo maggiore (MDD). Lo studio ha dimostrato miglioramenti statisticamente significativi nella gravità della depressione sia al Day 28 sia al Day 56 con una posologia orale giornaliera di 1 mg. Il trial, che ha coinvolto 183 adulti, ha testato due dosi (1 mg e 3 mg) contro placebo. La dose di 1 mg ha raggiunto l'obiettivo primario con una significativa riduzione del punteggio MADRS e ha mostrato risultati superiori in termini di risposta al trattamento e tassi di remissione. Osavampator, una prima classe di AMPA-PAM selettivo, è stato ben tollerato senza eventi avversi gravi, con cefalea e nasofaringite tra gli effetti indesiderati più comuni.
Neurocrine Biosciences (Nasdaq: NBIX) anunció resultados positivos de su estudio de fase 2 SAVITRI™ de osavampator (NBI-1065845) para el trastorno depresivo mayor (MDD). El estudio mostró mejoras estadísticamente significativas en la gravedad de la depresión tanto en el Día 28 como en el Día 56 con una dosis oral diaria de 1 mg. El ensayo, que involucró a 183 adultos, probó dos dosis (1 mg y 3 mg) frente a placebo. La dosis de 1 mg alcanzó el objetivo primario con una reducción significativa de la puntuación MADRS y mostró resultados superiores en respuesta al tratamiento y tasas de remisión. Osavampator, una primera clase selectiva de AMPA-PAM, fue bien tolerado sin eventos adversos graves, siendo la cefalea y la nasofaríngea los efectos secundarios más comunes.
뉴로크린 바이오사이언스(나스닥: NBIX)는 주요 우울 장애(MDD)를 위한 osavampator(NBI-1065845)의 2상 SAVITRI™ 연구에서 긍정적인 결과를 발표했습니다. 연구는 28일째와 56일째 모두에서 1 mg의 일일 경구 투여로 우울증 중증도의 통계적으로 유의한 개선을 보여주었습니다. 이 임상은 183명의 성인을 대상으로 하였고, 위약과 비교하여 두 가지 용량(1 mg 및 3 mg)을 시험했습니다. 1 mg 용량은 주요 평가 지표인 MADRS 점수 감소에서 유의미한 결과를 얻었고 치료 반응 및 관해율에서도 우수한 결과를 보였습니다. 최초의 AMPA-PAM 선택적 계열인 오사밤파토르(osavampator)는 심각한 이상사건 없이 잘 견뎌졌으며, 두통과 비인두염이 가장 흔한 부작용이었습니다.
Neurocrine Biosciences (NASDAQ : NBIX) a annoncé des résultats positifs de son étude de phase 2 SAVITRI™ sur l’osavampator (NBI-1065845) pour le trouble dépressif majeur (MDD). L’étude a démontré des améliorations statistiquement significatives dans la gravité de la dépression à la fois au Jour 28 et au Jour 56 avec une posologie orale quotidienne de 1 mg. L’essai, impliquant 183 adultes, a testé deux doses (1 mg et 3 mg) contre le placebo. La dose de 1 mg a atteint l’objectif principal avec une réduction significative du score MADRS et a montré des résultats supérieurs en termes de réponse au traitement et de taux de rémission. L’osavampator, une première classe sélective AMPA-PAM, a été bien toléré sans événements indésirables graves, les maux de tête et la nasopharyngite étant les effets secondaires les plus courants.
Neurocrine Biosciences (Nasdaq: NBIX) gab positive Ergebnisse aus seiner Phase-2-SAVITRI™-Studie zu Osavampator (NBI-1065845) bei der schweren depressiven Störung (MDD) bekannt. Die Studie zeigte statistisch signifikante Verbesserungen der Schwere der Depression sowohl am Tag 28 als auch am Tag 56 bei einer täglichen oralen Dosis von 1 mg. Die Studie, an der 183 erwachsene Teilnehmer beteiligt waren, testete zwei Dosen (1 mg und 3 mg) gegenüber Placebo. Die 1-mg-Dosis erreichte den primären Endpunkt mit einer signifikanten MADRS-Reduktion und zeigte sich bei der Behandlung Respond- und Remissionsraten überlegen. Osavampator, eine First-in-Class selektive AMPA-PAM, wurde gut vertragen ohne schwerwiegende unerwünschte Ereignisse; Kopfschmerzen und Nasopharyngitis waren die häufigsten Nebenwirkungen.
أعلنت شركة Neurocrine Biosciences (بورصة ناسداك: NBIX) عن نتائج إيجابية من دراستها من المرحلة الثانية SAVITRI™ لمركب osavampator (NBI-1065845) لاضطراب الاكتئاب الشديد (MDD). أظهرت الدراسة تحسنًا ذا دلالة إحصائية في شدة الاكتئاب في اليوم 28 وفي اليوم 56 مع جرعة فموية يومية قدرها 1 ملغ. التجربة التي شارك فيها 183 بالغًا اختبرت جرعتين (1 ملغ و3 ملغ) مقارنة بالدواء الوهمي. حققت جرعة 1 ملغ الهدف الأساسي مع انخفاض معنوي في درجة MADRS وأظهرت نتائج متفوقة في الاستجابة للعلاج ومعدلات الارتقاء. Osavampator، وهو فئة رائدة من AMPA-PAM الانتقائية، كان جيد التحمل ولم يسجل أي أحداث جانبية خطيرة، وكانت الصداع والنُزَلة الأنفية من أكثر الآثار الجانبية شيوعًا.
Neurocrine Biosciences（纳斯达克股票代码：NBIX）宣布其二期 SAVITRI™ 研究中关于 osavampator（NBI-1065845）用于重度抑郁症（MDD）的积极结果。该研究在第28天和第56天均显示出抑郁严重程度的统计学显著改善，日剂量为1 mg。该试验涉及183名成年人，比较了两种剂量（1 mg 和 3 mg）与安慰剂。1 mg 剂量在主要终点 MADRS 分数下降方面达到显著性，并在治疗反应率和缓解率方面显示出更优的结果。Osavampator 是首个同类选择性 AMPA-PAM，耐受性良好，未出现严重不良事件，头痛和鼻咽炎是最常见的副作用。
- None.
- None.
Insights
Neurocrine's osavampator shows promising Phase 2 results for treatment-resistant depression with novel mechanism and favorable safety profile.
Neurocrine's Phase 2 SAVITRI study of osavampator (NBI-1065845) has delivered statistically significant improvements in depression severity at both Day 28 and Day 56 with once-daily 1mg dosing. This represents a potentially groundbreaking advancement in depression treatment through a novel mechanism - positive allosteric modulation of AMPA receptors (AMPA-PAM). Most current antidepressants target monoamine systems (serotonin, norepinephrine), making this approach distinctly different.
The data quality is particularly compelling - the 1mg dose consistently outperformed placebo across multiple endpoints including the Montgomery-Åsberg Depression Rating Scale (MADRS) score reduction (primary endpoint) and the critical secondary endpoints of treatment response (≥50% MADRS reduction) and remission (MADRS ≤10). Interestingly, the lower 1mg dose showed superior efficacy to the 3mg dose, suggesting a potentially non-linear dose-response relationship typical of CNS-active compounds.
The safety profile appears remarkably clean for an antidepressant candidate. With no serious adverse events reported and common side effects (headache, nasopharyngitis) occurring at rates comparable to placebo, osavampator could potentially avoid the troublesome side effect profiles that limit many current antidepressants. Notably absent are common antidepressant side effects like significant weight gain, sexual dysfunction, or withdrawal symptoms.
This development addresses a substantial market need, as approximately 50% of MDD patients have inadequate responses to current treatments. As an adjunctive therapy specifically targeting this treatment-resistant population, osavampator could serve a significant unmet medical need while complementing rather than replacing existing first-line treatments.
The advancement to Phase 3 studies with the 1mg dose indicates Neurocrine's confidence in the development program and suggests potential commercialization within the next 2-4 years, pending successful late-stage trials.
"Major depressive disorder is one of the most common mental health conditions, and up to half of patients do not get sufficient relief from their current antidepressant regimen," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "We are encouraged by these results that show osavampator may help address this unmet need by modulating AMPA receptor activity."
In this dose-finding study, 183 adults 18 to 65 years of age were randomized in a 2:1:1 ratio to receive placebo, osavampator 1 mg or osavampator 3 mg once daily for eight weeks. Osavampator is an investigational potential first-in-class selective positive allosteric modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-PAM) in development as a potential adjunctive treatment for adults with major depressive disorder (MDD) who have an inadequate response to oral antidepressant treatment.
The study met its primary efficacy endpoint, showing a significant reduction in depression severity from baseline to Day 28 compared to placebo, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Secondary efficacy endpoints included the change in MADRS total score from baseline to Day 56.
Additional Secondary Efficacy Endpoints
Treatment Response (≥
- Day 56: osavampator 1 mg maintained statistical significance; 3 mg showed favorable but nominal difference
Remission (MADRS score ≤10):
- Day 56: osavampator 1 mg achieved statistically significant improvement versus placebo; 3 mg showed numerical improvement without statistical significance
Osavampator was generally well tolerated at both doses, with no serious adverse events or adverse events of special interest reported. The most commonly reported treatment-emergent adverse events (TEAEs) occurring in
TEAE Occurring in ≥
Preferred Term | Placebo (N=91) n (%) | osavampator 1 mg (N=45) n (%) | osavampator 3 mg (N=47) n (%) |
Any TEAE | 39 (42.9) | 25 (55.6) | 21 (44.7) |
Headache | 8 (8.8) | 5 (11.1) | 2 (4.3) |
Nasopharyngitis | 5 (5.5) | 2 (4.4) | 3 (6.4) |
Insomnia | 2 (2.2) | 1 (2.2) | 3 (6.4) |
Somnolence | 3 (3.3) | 3 (6.7) | 0 |
Nausea | 5 (5.5) | 1 (2.2) | 0 |
Dizziness | 5 (5.5) | 0 | 0 |
Data shown are the number of subjects reporting at least one occurrence of the event within each treatment group.
Results of an exploratory post hoc exposure-response analysis substantiate the continued evaluation of the 1 mg once-daily dosing in the phase 3 studies in MDD.
Poster presentations at Psych Congress 2025 include:
- Osavampator (NBI-1065845/TAK-653) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Depression Severity and is Well Tolerated in Adults with Major Depressive Disorder: Phase 2 SAVITRI Results
- Osavampator: A Selective Positive Allosteric Modulator of the AMPA Receptor (AMPA-PAM) in Development for the Treatment of Major Depressive Disorder
- The Functional Impact of Major Depressive Disorder on Patients' Daily Lives: A Qualitative Investigation of Patient and Clinician Perspectives
- Once-Daily Valbenazine Improves the Impacts and Symptoms of Tardive Dyskinesia Regardless of Psychiatric Diagnosis: Results from the Phase 4 KINECT-PROTM Study
- Once-Daily Valbenazine Improves the Impacts of Tardive Dyskinesia (TD) in Patients Who Met a Threshold for TD Remission: Post Hoc Analyses of Patient-Reported Outcomes from KINECT-PRO
- Valbenazine Improves Physical, Social, and Emotional Impacts on the Tardive Dyskinesia Impact Scale (TDIS™): Post Hoc Analyses of KINECT-PRO Data
- Estimation of the Minimal Clinically Important Difference and Longitudinal Change in the Tardive Dyskinesia Impact Scale, a Validated, Tardive Dyskinesia-Specific, Patient-Reported Outcome Measure
- Physical, Mental, and Socioemotional Functional Improvement Following Valbenazine Treatment for TD: a Case Series
- Once-Daily Valbenazine for the Treatment of Tardive Dyskinesia in Elderly Adults and Other Special Populations
- Valbenazine Improves Tardive Dyskinesia in Patients Regardless of Ethnicity or Race: Post Hoc Analyses of Long-Term Data from the KINECT® 4 Study
- A Qualitative, Interview-based Study of Patient, Caregiver, and Prescriber Rankings of Functional Outcome Improvements in Schizophrenia
About Osavampator and the Phase 2 SAVITRI™ Study
Osavampator (NBI-1065845) is an investigational selective positive allosteric modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-PAM) in development as a potential adjunctive treatment for adults with major depressive disorder (MDD) who have an inadequate response to oral antidepressant treatment. Neurocrine received an exclusive license to osavampator from Takeda Pharmaceutical Company Limited for all indications in all territories worldwide except Japan.
The Phase 2 SAVITRI study was a double-blind, placebo-controlled study designed to assess the efficacy and safety of investigational osavampator in adult subjects with MDD. The study enrolled 183 adults with a primary diagnosis of MDD and who had an inadequate response to current antidepressant treatment.
The Phase 3 Registrational Program
Following the announcement of positive top-line data from the Phase 2 SAVITRI study, Neurocrine initiated a Phase 3 registrational program of osavampator in January 2025, which includes five studies that are currently active and enrolling. For more information about the Phase 3 osavampator studies, please visit: ClinicalTrials.gov.
About Major Depressive Disorder
Major depressive disorder is a serious disorder characterized by a persistently depressed mood, loss of interest, poor concentration, and decreased energy, among other symptoms. According to the World Health Organization, MDD is one of the leading causes of disability, is a serious condition that presents an increased risk of suicide and self-harm and is associated with increased all-cause mortality. More than 21 million people in the
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, KINECT and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. SAVITRI, TDIS and KINECT-PRO are trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the clinical results from, and our future development plans with respect to, osavampator (NBI-1065845), the therapeutic potential and clinical benefits or safety profile of osavampator, and the potential benefits to be derived from certain of our products. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: data that we report may change following a more comprehensive review of the data related to the clinical study and such data may not accurately reflect the complete results of the clinical study; risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that regulatory submissions for our product candidates may not occur or be submitted in a timely manner; our future financial and operating performance; risks associated with our dependence on third parties for development, manufacturing and commercialization activities for our products and product candidates and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with
© 2025 Neurocrine Biosciences, Inc. All Rights Reserved
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-positive-new-data-from-phase-2-study-of-osavampator-in-adults-with-major-depressive-disorder-302562476.html
SOURCE Neurocrine Biosciences, Inc.
